Drug Resistance in Cancers: A Free Pass for Bullying

The cancer burden continues to grow globally, and drug resistance remains a substantial challenge in cancer therapy. It is well established that cancerous cells with clonal dysplasia generate the same carcinogenic lesions. Tumor cells pass on genetic templates to subsequent generations in evolutiona...

Full description

Bibliographic Details
Main Authors: Jing Li, Xiao Li, Qie Guo
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/11/21/3383
_version_ 1797468776153743360
author Jing Li
Xiao Li
Qie Guo
author_facet Jing Li
Xiao Li
Qie Guo
author_sort Jing Li
collection DOAJ
description The cancer burden continues to grow globally, and drug resistance remains a substantial challenge in cancer therapy. It is well established that cancerous cells with clonal dysplasia generate the same carcinogenic lesions. Tumor cells pass on genetic templates to subsequent generations in evolutionary terms and exhibit drug resistance simply by accumulating genetic alterations. However, recent evidence has implied that tumor cells accumulate genetic alterations by progressively adapting. As a result, intratumor heterogeneity (ITH) is generated due to genetically distinct subclonal populations of cells coexisting. The genetic adaptive mechanisms of action of ITH include activating “cellular plasticity”, through which tumor cells create a tumor-supportive microenvironment in which they can proliferate and cause increased damage. These highly plastic cells are located in the tumor microenvironment (TME) and undergo extreme changes to resist therapeutic drugs. Accordingly, the underlying mechanisms involved in drug resistance have been re-evaluated. Herein, we will reveal new themes emerging from initial studies of drug resistance and outline the findings regarding drug resistance from the perspective of the TME; the themes include exosomes, metabolic reprogramming, protein glycosylation and autophagy, and the relates studies aim to provide new targets and strategies for reversing drug resistance in cancers.
first_indexed 2024-03-09T19:11:16Z
format Article
id doaj.art-54648d7646b344c58c0b7bf5d8cb3795
institution Directory Open Access Journal
issn 2073-4409
language English
last_indexed 2024-03-09T19:11:16Z
publishDate 2022-10-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj.art-54648d7646b344c58c0b7bf5d8cb37952023-11-24T04:07:46ZengMDPI AGCells2073-44092022-10-011121338310.3390/cells11213383Drug Resistance in Cancers: A Free Pass for BullyingJing Li0Xiao Li1Qie Guo2The Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 266003, ChinaThe Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 266003, ChinaThe Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 266003, ChinaThe cancer burden continues to grow globally, and drug resistance remains a substantial challenge in cancer therapy. It is well established that cancerous cells with clonal dysplasia generate the same carcinogenic lesions. Tumor cells pass on genetic templates to subsequent generations in evolutionary terms and exhibit drug resistance simply by accumulating genetic alterations. However, recent evidence has implied that tumor cells accumulate genetic alterations by progressively adapting. As a result, intratumor heterogeneity (ITH) is generated due to genetically distinct subclonal populations of cells coexisting. The genetic adaptive mechanisms of action of ITH include activating “cellular plasticity”, through which tumor cells create a tumor-supportive microenvironment in which they can proliferate and cause increased damage. These highly plastic cells are located in the tumor microenvironment (TME) and undergo extreme changes to resist therapeutic drugs. Accordingly, the underlying mechanisms involved in drug resistance have been re-evaluated. Herein, we will reveal new themes emerging from initial studies of drug resistance and outline the findings regarding drug resistance from the perspective of the TME; the themes include exosomes, metabolic reprogramming, protein glycosylation and autophagy, and the relates studies aim to provide new targets and strategies for reversing drug resistance in cancers.https://www.mdpi.com/2073-4409/11/21/3383drug resistancetumor microenvironmentexosomesmetabolic reprogrammingglycosylationautophagy
spellingShingle Jing Li
Xiao Li
Qie Guo
Drug Resistance in Cancers: A Free Pass for Bullying
Cells
drug resistance
tumor microenvironment
exosomes
metabolic reprogramming
glycosylation
autophagy
title Drug Resistance in Cancers: A Free Pass for Bullying
title_full Drug Resistance in Cancers: A Free Pass for Bullying
title_fullStr Drug Resistance in Cancers: A Free Pass for Bullying
title_full_unstemmed Drug Resistance in Cancers: A Free Pass for Bullying
title_short Drug Resistance in Cancers: A Free Pass for Bullying
title_sort drug resistance in cancers a free pass for bullying
topic drug resistance
tumor microenvironment
exosomes
metabolic reprogramming
glycosylation
autophagy
url https://www.mdpi.com/2073-4409/11/21/3383
work_keys_str_mv AT jingli drugresistanceincancersafreepassforbullying
AT xiaoli drugresistanceincancersafreepassforbullying
AT qieguo drugresistanceincancersafreepassforbullying